Vitality Pharmacy

Placer Biosciences is a clinical-stage biotechnology company focused on the development of cannabinoid prodrugs for inflammatory and neurological disorders. The company's core platform utilizes enzymatic bioprocessing to create "cannabosides," which are glycoside prodrugs designed for targeted delivery to specific tissues, notably the gastrointestinal tract. This approach aims to provide the therapeutic benefits of cannabinoids, such as THC and CBD, to treat conditions like Inflammatory Bowel Disease (IBD) while minimizing psychoactive side effects. Placer Biosciences acquired these legacy assets from Malachite Innovations (formerly Vitality Biopharma) in 2024 and continues to advance its lead candidate, VBX-100, which has received FDA Orphan Drug Designation for pediatric ulcerative colitis. The company is headquartered in Folsom, California, and is led by the original scientific and financial team of the Vitality Biopharma drug development program.